RKIP loss also serves as a predictive marker for the progression and metastasis of liver [226,227], kidney [228], breast [229], ovarian [230], and colorectal cancers [231], as well as pancreatic ductal adenocarcinoma (PDAC) [232]. This evidence concerns the gene PEBP1 and colorectal cancer.